The CLAT study revealed consolidative local ablative therapy (LAT) to all metastatic sites as a feasible option for patients with EGFR-mutant oligometastatic NSCLC during first-line EGFR-TKI treatment, with significantly improved PFS and OS compared with the consolidative LAT to partial sites or observation alone.10 Yu et al11 reported that EGFR-mutant lung cancers with acquired resistance to EGFR-TKI therapy are amenable to local therapy to treat oligometastatic disease when combined with continued EGFR inhibition. This evidence concerns the gene EGFR and lung carcinoma.